Abivax presented late-breaking results from the ABTECT Trial, showing a 16.4% clinical remission rate with obefazimod at Week 8. The trials included patients with prior inadequate response to advanced therapy. No new safety signals were identified. The 50mg dose led to meeting primary and key secondary endpoints. A total of 1272 patients were enrolled with no serious infections observed. Obefazimod demonstrated efficacy in both trials, with a 19.3% and 13.4% clinical remission rate in ABTECT-1 and ABTECT-2, respectively. An investor conference call is scheduled for October 6 to discuss the results further.

Read more at GlobeNewswire: Abivax Announces Late-Breaking Presentation of 8-Week